{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

A survey to understand the treatment landscape in management of bipolar depression and place of Lumateperone in bipolar depression therapy

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire
  1. How many patients of bipolar disorder do you see in a month? *

  2. Among patients with bipolar disorder, what percentage present predominantly with depressive episodes? *

  3. How often do you find bipolar depression misdiagnosed as unipolar depression? *

  4. What are the most common challenges in diagnosing bipolar depression? *
  5. How would you rate the disease burden of bipolar depression on patients' quality of life? *

  6. Do you think the current treatment options adequately address bipolar depression? *

  7. In your clinical opinion, what are the key unmet needs in bipolar depression management? *
  8. What is your first-line treatment for bipolar depression? *

  9. Which mood stabilizers do you commonly prescribe for bipolar depression? (Select all that apply) *

  10. Which antipsychotics do you commonly prescribe for bipolar depression? (Select all that apply) *

  11. How frequently do you use antidepressants in bipolar depression? *

  12. When using antidepressants in bipolar depression, how do you typically combine them? *

  13. What is your most preferred second-line option when first-line fails? *
  14. What are your key goals in the treatment of bipolar depression? (Select top 3) *

  15. How important is metabolic profile in selecting an antipsychotic for bipolar depression? *

  16. What side effects concern you most in bipolar depression treatments? (Select all that apply) *

  17. Do you think patients with bipolar depression adhere well to current treatments? *

  18. Do you prescribe lumateperone as a monotherapy for bipolar depression? *

  19. Do you use lumateperone as an adjunctive treatment to lithium or valproate in bipolar depression?*

  20. What is the unique part of lumateperone's mechanism of action which differentiates it from other options? *

  21. In your view, what are the key benefits of Lumateperone in the management of bipolar depression? *
  22. What are your concerns or barriers to using lumateperone in bipolar depression patients? *
  23. What type of bipolar depression patients would you consider ideal for lumateperone? *
  24. How would you rate lumateperone compared to other antipsychotics you use for bipolar depression? *

  25. Have you noticed a lower incidence of mania or hypomania episodes in bipolar depression patients treated with lumateperone? *

  26. What specific patient outcomes would encourage your confidence in lumateperone? *
  27. Do you consider lumateperone effective in managing bipolar depression patients with mixed features or atypical symptoms? *

  28. What role do patient preferences play in your treatment decisions for bipolar depression? *

  29. Do you see a role for lumateperone in treatment-resistant bipolar depression? *

  30. Have you observed differences in response between bipolar I and bipolar II depression patients when using current treatment options? *

  31. Which symptoms of bipolar depression are most difficult to manage in your experience? *
  32. How often do your bipolar depression patients discontinue treatment due to side effects? *

  33. Do you actively monitor metabolic parameters (e.g., weight, glucose, lipids) in patients on antipsychotics for bipolar depression? *

  34. In your experience, how long does it typically take for patients to show noticeable improvement on antipsychotics for bipolar depression? *

  35. Would you consider lumateperone in patients with bipolar depression who are obese or have metabolic syndrome? *

  36. In your opinion, how does lumateperone compare to quetiapine in terms of tolerability? *

  37. In which of the following patient subgroups in bipolar depression patients would you feel most confident prescribing lumateperone? (Select all that apply) *

  38. How do you foresee the role of Lumateperone evolving in bipolar depression management over the next 5 years? *
  39. How do you educate and involve patients in treatment decisions regarding lumateperone for bipolar depression? *
  40. In your experience, what key factors contribute to long-term stability and relapse prevention in bipolar depression? *